Ferreira JP, Inzucchi SE, Meinicke T, et al. - Empagliflozin lowered uric acid (UA) levels as well as the composite of gout episodes and anti-gout drug prescriptions. Such clinically significant findings extend empagliflozin's relevance as a potential anti-gout medication in type 2 diabetes (T2D) patients beyond its well-established cardio-renal advantages.

• In total, 7,020 T2D patients were randomized to either empagliflozin (10 or 25mg) or placebo.

• Empagliflozin decreased serum UA levels compared with placebo: week 52 adjusted mean treatment difference = −0.37 mg/dL; this was more significant in individuals with baseline UA ≥ 7.0 mg/dL vs < 7.0 mg/dL: week 52 adjusted mean treatment difference = -0.56 mg/dL and -0.30 mg/dL, respectively.

• Data reported that 5.2% of 6,607 patients who were not using anti-gout drugs at baseline had a gout episode or started anti-gout treatment, compared with 3.6% in the placebo and empagliflozin groups, respectively: HR (95%CI) =0.67 (0.53, 0.85).

• The reduction in the composite with empagliflozin was due to both components of the composite outcome.

• Both empagliflozin doses reduced risk in the same way.